Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6238958 | 0.86 | — | — | |
| SCHEMBL17752196 | 0.80 | BTN3A1 (0.31) | — | |
| SCHEMBL22062854 | 0.78 | — | — | |
| SCHEMBL7939281 | 0.78 | EP300 (0.39) | ALDH1A1 | |
| SCHEMBL7939276 | 0.78 | EP300 (0.39) | ALDH1A1 | |
| Pivalate SCHEMBL31298532 | 0.76 | CD81 (0.36) | ALDH1A1 | |
| SCHEMBL7303138 | 0.75 | DGAT1 (0.31) | — | |
| SCHEMBL7303141 | 0.75 | DGAT1 (0.31) | — | |
| SCHEMBL26366157 | 0.75 | — | — | |
| SCHEMBL8005980 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180170953-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD (CY) | 2018-06-21 | — | — | US | disclosed |
| US-9890187-B2 | Prototype systems of theranostic biomarkers for in vivo molecular management of cancer | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD. (CY) | 2018-02-13 | — | — | US | disclosed |
| US-20160376298-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | EPOS-IASIS RESEARCH AND DEVELOPMENT, LTD (CY) | 2016-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160376298-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | TP53, MKI67, FLT3 | ALDH1A1 1759/4885TDP1 1430/4885 |
| US-20180170953-A1 | PROTOTYPE SYSTEMS OF THERANOSTIC BIOMARKERS FOR IN VIVO MOLECULAR MANAGEMENT OF CANCER | TP53, MKI67, FLT3 | ALDH1A1 1759/4885TDP1 1430/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.